Navigation Links
Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc
Date:11/6/2014

Baltimore, MD, November 6, 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused on research in aging and age related diseases announced a research collaboration with the international leader in personalized medicine of cancer, Champions Oncology, Inc (OTC: CSBR).

"There are many companies utilizing advances in genomics for personalized medicine, but Champions Oncology's TumorGraft technology is unique in a way that it can validate the chemotherapy regimen experimentally generating vast amounts of valuable data. Our bioinformatic analysis showed that molecular signatures of patient tumor grafts in mice are very similar to signatures of cancer in patients before and after treatment. We established this research collaboration to further validate these preliminary findings", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

Champions TumorGrafts are a personalized approach used to guide physician treatment decisions for cancer patients. A piece of the patient's living tumor is removed during surgery or biopsy and engrafted in immune-deficient mice. After the TumorGraft grows, still closely resembling the patient's tumor, Champions Oncology tests drug treatments in the TumorGraft and measures the response. TumorGraft has demonstrated high rates of predictability using multiple therapies, including single-agent and combination, chemotherapy regimens and targeted biological drugs.

Every TumorGraft is preserved as a living sample for future patient use. These banked TumorGrafts can be re-grown and tested in the event of cancer progression or recurrence. In oncology drug development, TumorGraft models are utilized extensively by pharmaceutical and biotechnology organizations to predict the clinical effectiveness of their compounds in targeted patient populations.

"Our preliminary collaboration with Insilico Medicine showed some exciting results that may be of interest to both the academic and industry communities", said KerenPaz, chief Scientific Officer at Champions Oncology.

In the scope of this research collaboration Insilico Medicine will analyze a portion of Champions Oncology gene expression data sets from tumor grafts before and aftertreatment with chemotherapy drugs and compare the signaling pathway activation state (SPAS) changes with the SPAS changes in human patients.

"Champions' Tumorgraft technology stems from many years of breakthrough science generated in the most credible, productive and innovative cancer research laboratories headed by Dr. David Sidransky, who's work we greatly admire. We believe that the TumorGraft technology has broad applications in drug discovery and drug repurposing in aging and age-related diseases that were previously overlooked. This research collaboration may pave the way for a comprehensive drug discovery and development pipeline, where drugs and drug candidates may be selected and prioritized using in silico approaches and tested in human tissues engrafted into Champions Oncology mice or other animal models", said Qingsong Zhu, PhD, Chief Operating Officer, Insilico Medicine, Inc.


'/>"/>

Contact: Michael Petr
michael.petr@insilicomedicine.com
InSilico Medicine, Inc.
@InSilicoMeds
Source:Eurekalert

Related biology news :

1. InSilico Medicine CEO to present at Oxford University
2. Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago
3. Timing is everything in new nanotechnology for medicine, security and research
4. Cancer research implies future for personalized medicine, reduction in animal testing
5. Medicine, energy topics of Kavli lectures at American Chemical Society meeting
6. After the Genome tackles tough questions about medicine, miracles and morality
7. Young malaria parasites refuse to take their medicine, may explain emerging drug resistance
8. Personalized health care will revolutionize 21st century medicine, says NJIT professor
9. University of Maryland School of Medicine, NIH study pinpoints brain areas role in learning
10. HITLAB Announces Inaugural HITLAB Innovators Summit
11. Elsevier announces launch of open journal: Biomolecular Detection and Quantification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2018)... LEXINGTON, Mass. (PRWEB) , ... August 14, 2018 ... ... in medical device compliance and commercialization, is announcing the keynote for their ... LumiraDx, has been announced as keynote speaker for NAVIGATE2018 , Cognition’s annual ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... cell and viral gene therapy manufacturing facility has won Engineering News-Record (ENR) Texas ... entries were submitted for the Best Projects competition. The judges selected 42 projects ...
(Date:8/7/2018)... SAN DIEGO (PRWEB) , ... August 07, 2018 ... ... biosensors that accelerate pharmaceutical and biotherapeutics development, announces a new publication titled, ... journal Bioorganic & Medicinal Chemistry. The paper prominently features use of Agile R100, ...
Breaking Biology News(10 mins):
(Date:7/25/2018)... , ... July 25, 2018 , ... ... on the significant impact of a biofield energy treated nutraceutical to improve skin ... research assessed biomarkers for skin health and reported the following results:, ...
(Date:7/25/2018)... , ... July 25, 2018 , ... ... (IoT) Systems Innovator, joined the board of the Indiana India Business Council (IIBC), ... unanimously elected today by the current board of directors, McDonald joins an impressive ...
(Date:7/22/2018)... Mass. (PRWEB) , ... July 19, 2018 , ... ... Pottorff, a driven channel professional has joined their team. With more than ten ... business-growth initiatives, Adam will deliver his expertise as CallTower’s Channel Director for the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Turesol Staffing Solutions ... Unit Leader, will moderate a discussion on the subject of “Process capabilities as they ... & Expo . The theme of this year’s meeting is “Driving innovation to advance ...
Breaking Biology Technology: